Evidence map›Paper›PMID 37989379›Full record

SynthesisBMJ open2023

Association between dyslipidaemia and dry eye disease: a systematic review and meta-analysis.

Yingsi Li, Luoying Xie, Wenjing Song, Shudi Chen, Yu Cheng, Yuan Gao, Meiting Huang, Xiaoming Yan, Songlin Yang

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Link Between Metabolic Syndrome, Inflammation, and Eye Diseases.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yingsi Li *Department of Ophthalmology, Peking University First Hospital, Beijing, China.ORCID 0000-0002-9926-1803
Luoying Xie *Department of Ophthalmology, Peking University First Hospital, Beijing, China.
Wenjing SongDepartment of Ophthalmology, Peking University First Hospital, Beijing, China.
Shudi ChenDepartment of Ophthalmology, Peking University First Hospital, Beijing, China.
Yu ChengDepartment of Ophthalmology, Peking University First Hospital, Beijing, China.
Yuan GaoDepartment of Ophthalmology, Peking University First Hospital, Beijing, China.
Meiting HuangDepartment of Ophthalmology, Peking University First Hospital, Beijing, China.
Xiaoming YanDepartment of Ophthalmology, Peking University First Hospital, Beijing, China.
Songlin YangDepartment of Ophthalmology, Peking University First Hospital, Beijing, China songlin.yang@foxmail.com.
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report a systematic review and meta-analysis of the association between dry eye disease (DED) and dyslipidaemia.

methodsPubMed, Embase, Web of Science and Cochrane Library were systematically searched from January 2000 to December 2021. We included observational studies to assess the correlation of DED with meibomian gland dysfunction and dyslipidaemia without any language restrictions. The pooled OR with 95% CI was calculated in Stata V.15.

resultsOf 6727 identified studies, 18 studies (21 databases) with a total of 2 663 126 patients were analysed in our meta-analysis. The results showed that DED risk was associated with dyslipidaemia (OR=1.53, 95% CI: 1.41 to 1.66, p=0.001), especially elevated total cholesterol levels (OR=1.57, 95% CI: 1.25 to 1.99, p<0.001), elevated low-density lipoprotein cholesterol levels (OR=1.13, 95% CI: 1.06 to 1.20, p<0.001) and high-density lipoprotein cholesterol levels (OR=1.06, 95% CI: 1.01 to 1.11, p<0.001), but not with serum triglyceride levels. Moreover, having a history of lipid-lowering drug use (OR=1.41, 95% CI: 1.19 to 1.67, p<0.001) was also found to be positively associated with DED risk.

conclusionsThe findings suggested that dyslipidaemia and lipid-lowering drug use might be associated with an increased risk of DED. More evidence is needed to confirm the findings by prospective studies. PROSPERO REGISTRATION NUMBER: CRD42022296664.

Indexed as

Dry Eye SyndromesDyslipidemiasCholesterolHumansLipidsProspective StudiesCholesterolLipidscorneal and external diseasesinformation managementmedical ophthalmology

Identifiers

PMID37989379
PMCPMC10668302
OpenAlexW4388871150

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.